South Africa was “bullied” into signing one-sided contracts with Covid-19 vaccine suppliers that forced the government to pay more than the European Union but offered little protection against delivery failures, according to an advocacy group.
For instance, Johnson & Johnson charged South Africa $10 a dose, 15% more than the company charged the European Union, while the government was required to pay a non-refundable down payment of $27.5 million. Pfizer also charged $10 a dose, which was 33% more than the $6.75 charged the African Union. South Africa was required to pay $40 million in advance, only half of which was refundable.
Meanwhile, the Serum Institute of India planned to charge South Africa $5.35 a dose for Covishield, its generic version of a Covid-19 vaccine developed by AstraZeneca and Oxford University, which was 2.5 times more than it charged the European Union. However, South Africa subsequently suspended its order over safety concerns.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect